Templates by BIGtheme NET
hc-blog-2

HC Stocks Newsbeat! GlaxoSmithKline plc (GSK), ACADIA Pharmaceuticals Inc. (ACAD)

Shares of GlaxoSmithKline plc (ADR) (NYSE:GSK) ended Wednesday session in red amid volatile trading. The shares closed down -0.06 points or -0.14% at $42.08 with 2.35 million shares getting traded. Post opening the session at $42.13, the shares hit an intraday low of $41.85 and an intraday high of $42.19 and the price vacillated in this range throughout the day. The company has a market cap of $101.27 billion and the numbers of outstanding shares have been calculated to be 4.87 billion shares.

GlaxoSmithKline plc (ADR) (GSK) discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) ended Wednesday session in red amid volatile trading. The shares closed down -1.10 points or -4.09% at $25.78 with 2.57 million shares getting traded. Post opening the session at $26.79, the shares hit an intraday low of $25.37 and an intraday high of $27.11 and the price vacillated in this range throughout the day. The company has a market cap of $3.05 billion and the numbers of outstanding shares have been calculated to be 119.75 million shares.

ACADIA Pharmaceuticals Inc. (ACAD) announced the appointment of Todd S. Young as Executive Vice President, Chief Financial Officer. Mr. Young reports to Steve Davis, ACADIA’s President and Chief Executive Officer.

“Todd is a seasoned leader with significant financial and operational experience in the biopharmaceutical industry,” said Steve Davis. “His proven finance and leadership skills will be key as we bring NUPLAZID™ (pimavanserin) to patients in need, seek to maximize the significant opportunities ahead for pimavanserin, and deliver on our vision of building a leading CNS company. We welcome Todd to our team and look forward to his contributions.”

 

 

 

About James Smith

James Smith is one of the best author of health care. His articles have appeared in a number of health care sites before and now he is writing on health care for us on regular basis.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

ăn dặm kiểu NhậtResponsive WordPress Themenhà cấp 4 nông thônthời trang trẻ emgiày cao gótshop giày nữdownload wordpress pluginsmẫu biệt thự đẹpepichouseáo sơ mi nữhouse beautiful